Coronary Heart Disease, Family History and Public Health: From Familial Hypercholesterolemia to Elevated Lipoprotein A

Print
Related Pages

April 27, 2023, 11:00 am – 12:00 noon

Heart disease remains the number one cause of death in the United States and around the world. In addition to known risk factors for heart disease, family history plays an important role. In the past decade, major advances have occurred at the intersection of genomics, heart disease and public health. Familial hypercholesterolemia (FH), a genetic disorder of cholesterol metabolism affecting millions of people, has emerged as public health genomics priority for preventing premature morbidity and mortality from heart disease. In addition, elevated lipoprotein (a) (Lp(a)) increases the risk of coronary heart disease, occur in 1 in 5 people, have a strong genetic basis, and accentuate the cardiovascular risk from FH and other risk factors.

This seminar will explore advances in FH and Lp(a) and the emerging clinical and public health approaches to reducing the burden of cardiovascular disease using genetics and family history.

Laurence Sperling
Laurence Sperling, MD, FACC, FACP, FAHA, FASPC

Katz Emory University Professor in Preventive Cardiology
Professor of Global Health
Executive Director, Million Hearts
Centers for Disease Control and Prevention (CDC) / Centers for Medicare and Medicaid Services (CMS)

Ijeoma Isiadinso
Ijeoma Isiadinso MD, MPH, FACC, FASNC

Associate Professor of Medicine
Division of Cardiology
Medical Director, Emory Center for Heart Disease Prevention

Selected References

  1. Applying implementation science to improve care for familial hypercholesterolemia. Jones LK, et al, Curr Opin Endocrinol Diabetes Obes. 2022 Apr 1;29(2):141-15
  2. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A  Global Call to Action. J Patel et al, JAMA Cardiology, Feb 2020
  3. Genetic testing for familial hypercholesterolemia-past, present, and future. Futema M, et al, J Lipid Res. 2021;62:100139
  4. Strategies for screening for familial hypercholesterolaemia in primary care and other community settings. Qureshi N, et al, Cochrane Database Syst Rev. 2021 Oct 7
  5. Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care. Loh WJ, et al. Front Genet. 2022 Apr 27;13:905941
  6. Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime? Alonso R, et al, Curr Atheroscler Rep. 2022 Apr 7.
  7. Lipoprotein(a) as Part of the Diagnosis of Clinical Familial Hypercholesterolemia. Langsted A, et al, Curr Atheroscler Rep. 2022 Apr;24(4):289-296
  8. Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target. Di Fusco SA, et al, Heart. 2022 Mar 14
  9. Lipoprotein(a) and cardiovascular diseases. H Mikensas et al, JAMA, July 2021

Hosted by

  • Division for Heart Disease and Stroke Prevention
  • Office of Genomics and Precision Public Health